SPEAKERS

SAMPLE OF KEYNOTE SPEAKERS AND THEIR CASE STUDIES

Oleksandr GORBENKO

Global Patient Centricity Director

CASE STUDY / DAY 1

Patient Engagement Strategies Across the Medicines Development Continuum: Ipsen Best Practices

In this presentation we will overview the best patient engagement strategies across the medicines development continuum and focus on our actions to improve patient recruitment and retention.

  • Overview of best PE strategies across the medicines development continuum
  • What we can do to improve patient recruitment and retention and some lessons learned over the COVID-19 pandemic
  • Initiatives we have already implemented at Ipsen and in collaboration with our partners
  • Further considerations
CASE STUDY / DAY 1

Patient-Relevant Clinical Trials: Early Patient Involvement in the Design of Development Programmes

Active involvement of patient representatives early in the design phase of development programmes has become vital for the successful conduct of clinical trials. Patient panels discuss what patients expect from clinical trials, and what they need to gain a positive experience of participating in a trial. Patient boards help define patient-relevant outcomes by specifying what constitutes real benefit and value for patients. This session will reflect on the lessons learned to date from involving patient representatives in clinical trial design and explore the path forward.

  • Comparing the perspectives of industry, research and patients
  • What are best practices in involving patient representatives in clinical trial design?
  • What are key challenges, and how are they overcome?
  • Discussing the way to go to take patient involvement to the next level

Gunnar SCHROEFEL

Global Director Patient Advocacy

SUMMIT WILL HOST SPEAKERS FROM THE WORLD’S LEADING COMPANIES

Gunnar SCHROEFEL

Global Director Patient Advocacy

CASE STUDY DAY 1

Patient-Relevant Clinical Trials: Early Patient Involvement in the Design of Development Programmes

Active involvement of patient representatives early in the design phase of development programmes has become vital for the successful conduct of clinical trials. Patient panels discuss what patients expect from clinical trials, and what they need to gain a positive experience of participating in a trial. Patient boards help define patient-relevant outcomes by specifying what constitutes real benefit and value for patients. This session will reflect on the lessons learned to date from involving patient representatives in clinical trial design and explore the path forward.

• Comparing the perspectives of industry, research and patients
• What are best practices in involving patient representatives in clinical trial design?
• What are key challenges, and how are they overcome?
• Discussing the way to go to take patient involvement to the next level

Kimberley KALLSEN

Head of Patient & Site Journey, Global Clinical Development & Operations

CASE STUDY DAY 1

The Journey of Bringing the Voice of Patients and Sites into End-to-End Clinical Development

Bringing the voice of patients and sites into end-to-end clinical development will provide a good trial experience for trial participants, bring innovative treatments to patients faster by accelerating clinical development and ensure that new treatments fulfil patients’ needs and expectations.

• Examples for understanding the voice of patients and sites and bringing it into clinical development
• The importance of bringing all stakeholders together, including partnerships with patient organisations and healthcare professionals
• Challenges and future opportunities

Oleksandr GORBENKO

Global Patient Centricity Director

CASE STUDY DAY 2

Patient Engagement Strategies Across the Medicines Development Continuum: Ipsen Best Practices

In this presentation we will overview the best patient engagement strategies across the medicines development continuum and focus on our actions to improve patient recruitment and retention.

• Overview of best PE strategies across the medicines development continuum
• What we can do to improve patient recruitment and retention and some lessons learned over the COVID-19 pandemic
• Initiatives we have already implemented at Ipsen and in collaboration with our partners
• Further considerations

Karin BLUMER

Director Global Patient Engagement

CASE STUDY DAY 2

Revolutions Need Evolution - How Cell and Gene Therapies Transform Patient Engagement

In 2017, the FDA approved the first-ever CAR-T cell therapy for a rare hematologic malignancy. This approval was considered a scientific revolution by many. Since then, several other gene therapies entered the market. They all come with new key characteristics - high value one-time therapies with long-term value and some even with a curative potential. This has profound implications on interactions of sponsors with patients on the one side and the whole ecosystem on the other side. This talk will give an oversight on new challenges and opportunities as well as an outlook to potential ways ahead.

• Cell and gene therapies
• CAR-T cell therapies
• Evolving patient engagement in one-time therapies

Marta Garcia MANRIQUE

R&D. Chief Patient Officer

CASE STUDY DAY 1

Patient Engagement on Clinical Research: Challenges and Opportunities

The value of incorporating patients’ insights on clinical development is now widely accepted, however, the incorporation of patient engagement in the development of new drugs is still very variable. The presentation will address this situation identifying possible reasons and possible solutions.

• The value of patient engagement on medical research
• The current situation of patient engagement
• Challenges of PE in practice
• New possibilities and examples

Kimberley KALLSEN

Head of Patient & Site Journey, Global Clinical Development & Operations

CASE STUDY / DAY 2

The Journey of Bringing the Voice of Patients and Sites into End-to-End Clinical Development

Bringing the voice of patients and sites into end-to-end clinical development will provide a good trial experience for trial participants, bring innovative treatments to patients faster by accelerating clinical development and ensure that new treatments fulfil patients’ needs and expectations. 

  • Examples for understanding the voice of patients and sites and bringing it into clinical development
  • The importance of bringing all stakeholders together, including partnerships with patient organisations and healthcare professionals
  • Challenges and future opportunities
CASE STUDY / DAY 2

Revolutions Need Evolution - How Cell and Gene Therapies Transform Patient Engagement

In 2017, the FDA approved the first-ever CAR-T cell therapy for a rare hematologic malignancy. This approval was considered a scientific revolution by many. Since then, several other gene therapies entered the market. They all come with new key characteristics – high value one-time therapies with long-term value and some even with a curative potential. This has profound implications on interactions of sponsors with patients on the one side and the whole ecosystem on the other side. This talk will give an oversight on new challenges and opportunities as well as an outlook to potential ways ahead.

  • Cell and gene therapies
  • CAR-T cell therapies
  • Evolving patient engagement in one-time therapies

Karin BLUMER

Director Global Patient Engagement

Marta Garcia MANRIQUE

R&D. Chief Patient Officer

CASE STUDY / DAY 2

Patient Engagement on Clinical Research: Challenges and Opportunities

The value of incorporating patients’ insights on clinical development is now widely accepted, however, the incorporation of patient engagement in the development of new drugs is still very variable. The presentation will address this situation identifying possible reasons and possible solutions.

  • The value of patient engagement on medical research
  • The current situation of patient engagement
  • Challenges of PE in practice
  • New possibilities and examples

Excellent conference. Great discussions. The size of this conference allows for great dialogues.

Global Patient Centricity Director, Ipsen

Event programme

Fill your details in the form and we will
send you the whole brochure filled with all details

Your copy of the brochure is prepared.

Inside you will find

  • What keynote speakers will be taking part in the exclusive speaking panel
  • What Case Studies will be discussed by our senior corporate speakers
  • The minute by minute breakdown of the conference